Libertas Patient Summary – Metastatic Castration Sensitive

Janssen Patient Summaries, Patient Summaries

Coming Soon


A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC).

Brief Summary:

The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level < 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted hot flash score


Janssen Research & Development, LLC

Clinical Information:

  • NCT Number: NCT05884398
  • Title: A Study of an Intermittent ADT Approach with Apalutamide Monotherapy in Participants With mCSPC (LIBERTAS)

Use the “clinical trials glossary” and “dictionary” for words, phrases and treatments that you may not understand.

Register your interest or comments about this trial with PHEN

Please Note: This information is provided for educational and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.

Pin It on Pinterest